TY - JOUR
T1 - Next-generation sequencing in thyroid cancers
T2 - Do targetable alterations lead to a therapeutic advantage?: A multicenter experience
AU - Moore, Assaf
AU - Bar, Yael
AU - Maurice-Dror, Corinne
AU - Finkel, Inbar
AU - Goldvaser, Hadar
AU - Dudnik, Elizabeth
AU - Goldstein, Daniel A.
AU - Gordon, Noa
AU - Billan, Salem
AU - Gutfeld, Orit
AU - Wolf, Ido
AU - Popovtzer, Aron
N1 - Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/6/25
Y1 - 2021/6/25
N2 - AbstractRadioiodine-refractory thyroid cancers (IRTCs) are uncommon and have a poor prognosis. Treatment options for radioiodine-refractory and anaplastic tumors (ATCs) are limited. Although the genomic landscape of thyroid cancer has been studied, there is little evidence on whether next-generation sequencing (NGS) findings translate to tumor control.We analyzed all patients with IRTC and ATC who underwent commercially available NGS in 3 cancer centers.Twenty-two patients were identified, 16 patients with IRTCs and 6 patients with ATCs. Eighteen (82%) had targetable findings in NGS, nine patients were treated accordingly. Median progression-free survival for targeted treatment was 50 months [95% confidence interval (CI95%) 9.8-66.6] and2 months (CI95% 0.2-16.5) for IRTC and ATC, respectively. Of 4 patients who achieved durable responses of 7 to 50 months, 2 are ongoing. The estimated median OS of IRTC receiving targeted treatment was not reached (CI95% 89.7-111.4 months) and was 77.8 months (CI95% 52.5-114.6) for patients treated conventionally (P = .3).NGS may detect clinically significant genetic alterations and benefit patients with advanced thyroid cancers.
AB - AbstractRadioiodine-refractory thyroid cancers (IRTCs) are uncommon and have a poor prognosis. Treatment options for radioiodine-refractory and anaplastic tumors (ATCs) are limited. Although the genomic landscape of thyroid cancer has been studied, there is little evidence on whether next-generation sequencing (NGS) findings translate to tumor control.We analyzed all patients with IRTC and ATC who underwent commercially available NGS in 3 cancer centers.Twenty-two patients were identified, 16 patients with IRTCs and 6 patients with ATCs. Eighteen (82%) had targetable findings in NGS, nine patients were treated accordingly. Median progression-free survival for targeted treatment was 50 months [95% confidence interval (CI95%) 9.8-66.6] and2 months (CI95% 0.2-16.5) for IRTC and ATC, respectively. Of 4 patients who achieved durable responses of 7 to 50 months, 2 are ongoing. The estimated median OS of IRTC receiving targeted treatment was not reached (CI95% 89.7-111.4 months) and was 77.8 months (CI95% 52.5-114.6) for patients treated conventionally (P = .3).NGS may detect clinically significant genetic alterations and benefit patients with advanced thyroid cancers.
KW - anaplastic thyroid cancer
KW - differentiated thyroid cancer
KW - next-generation sequencing
KW - targeted treatment
UR - http://www.scopus.com/inward/record.url?scp=85108998475&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000026388
DO - 10.1097/MD.0000000000026388
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34160418
AN - SCOPUS:85108998475
SN - 0025-7974
VL - 100
SP - E26388
JO - Medicine (United States)
JF - Medicine (United States)
IS - 25
ER -